Efficacy and Safety of Sirolimus to Vascular Anomalies

Inclusion Criteria: * All patients included in the present research must be diagnosed with one of the following vascular anomalies: 1. Kaposiform Hemangioendotheliomas without Kasabach-Merritt Phenomenon 2. Tufted Angioma without Kasabach-Merritt Phenomenon 3. Capillary Malformations 4. Lymphatic Malformations 5. Venous Malformations 6. Capillary-Venous Malformation (CVM) 7. Capillary-Lymphatic Malformation (CLM) 8. Lymphatic-Venous Malformation (LVM) 9. Capillary-Lymphatic-Venous Malformation (CLVM) 10. Multifocal Lymphangiomatosis and Thrombocytopenia (MLT) * Patients must be 0 - 18 years of age at the time of study entry. * Without functional impairment requiring treatment of corticosteroid. * Organ function requirements: * Adequate liver function Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)for age, and alanine transaminase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x upper limit normal (ULN) for age. * Adequate renal function 0-5 years of age maximum serum creatinine (mg/dL) of 0.8 6-10 years of age maximum serum creatinine (mg/dL) of 1.0 11-15 years of age maximum serum creatinine (mg/dL) of 1.2 16-18 years of age maximum serum creatinine (mg/dL) of 1.5 * Adequate bone marrow function: Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10 to the ninth/Liter * Consent of parents (or the person having parental authority in families): Signed and dated written informed consent. Exclusion Criteria: * Allergy to sirolimus or other rapamycin analogues. * Allergy to sirolimus or other rapamycin analogues. * Any known evidence of significant local or systemic uncontrolled infection, defined as receiving intravenous antibiotics at the time of randomization. * Patients must not be known to be Human Immunodeficiency Virus positive or known immunodeficiency. Testing is not required unless a condition is suspected. * Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe malnutrition, chronic liver or renal disease, active upper gastrointestinal tract ulceration). * Impairment of gastrointestinal function or chronic gastrointestinal disease that may significantly alter the absorption of sirolimus. * Patients who have a history of malignancy. * Patients with an inability to participate or to follow the study treatment and assessment plan. * Patients who have a history of treatment with sirolimus or other mTOR inhibitor.